// App-Quantinova.ai

SAT-0986 : Safety and Efficacy of Empagliflozin Monotherapy in a 52-Week Study in Japanese Patients with Type 2 Diabetes Mellitus

Researchers

Presenter

  • Takashi Kadowaki

Principal Investigators

  • Masakazu Haneda

  • Nobuya Inagaki

  • Atsushi Taniguchi

  • Kazuki Koiwai

  • Henning Rattunde

  • Uli C Broedl

  • Hans-Juergen Woerle

Medical Centers

  • Asahikawa Medical Univ., Asahikawa, Japan.

  • Univ. of Tokyo, Tokyo, Japan.

  • Graduate School of Medicine Kyoto University, Kyoto, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

  • Urology

Disease

  • Type 2 diabetes mellitus

  • Urinary tract infections

  • Diabetes

Biomarkers

  • GC Vitamin D Binding Protein

  • Hemoglobin A1c

  • Sex hormone binding globulin

  • Body mass index

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved